Reports
Sale
Global Phenylketonuria Treatment Market Size, Trends, Growth: By Disease Type: Hyperphenylalaninemia, Mild PKU, Moderate or Variant, Classic PKU; By Product Type: Dietary Supplements, Drugs; By Route of Administration: Oral, Parenteral, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Phenylketonuria Treatment Market Outlook
The global phenylketonuria treatment market stood at a value of around USD 446.7 million in 2020. The industry is further projected to grow at a CAGR of 10% during the forecast period of 2023-2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing prevalence of phenylketonuria and the rising awareness regarding its treatment is driving the growth of the phenylketonuria treatment market globally. The expected increase in the production and commercialisation of new drugs would further fuel the industry growth in the coming years.
Properties and Applications
Phenylketonuria or PKU, is a genetic disorder due to which phenylalanine levels in blood increases. Phenylalanine is an amino acid that is derived from food and diet. The elevated phenylalanine level may cause intellectual disability and other health-related issues. Because of the excess phenylalanine in the body, children with phenylketonuria may have a musty odour. Further, patients appear to have light skin and hair colour, as well as other skin conditions like eczema.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global phenylketonuria treatment market can be broadly categorised based on segments like product types, route of administration, distribution channels, and regions.
- Product Type:
- Dietary Supplement
- Drugs
- Kuvan
- Palynziq
- CNSA-001
- SYNB1618
- Route of Administration:
- Oral
- Parenteral
- Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Paediatric Clinics
- Drug Stores
The EMR report looks into the regional phenylketonuria treatment markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global phenylketonuria treatment market is being driven by the growing incidence of PKU, increased R&D activities, rising health concern, enhanced diagnostics facilities, and improved health care infrastructure.
The dietary supplement segment, among other product types, accounts for a significant share in the industry owing to its increased preference among health care professionals to treat patients with phenylketonuria. The oral route remains the more preferred route of administration over parenteral due to its ease of administration and convenience. Region-wise, while North America is expected to account for the largest share in the industry, the Asia Pacific is anticipated to see the highest growth rate over the forecast period owing to the presence of increased population and the growing investment in the R&D of phenylketonuria drugs in the region.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global phenylketonuria treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- BioMarin Pharmaceutical Inc.
- Synlogic, Inc.
- Retrophin, Inc.
- Codexis, Inc.
- SOM Innovation Biotech, S.A.
- Homology Medicines, Inc.
- Others
The EMR report gives an in-depth insight into the phenylketonuria treatment market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Product Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Phenylketonuria Treatment Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Phenylketonuria Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Phenylketonuria Epidemiology (2016-2031)
5.3 Europe Phenylketonuria Epidemiology (2016-2031)
5.4 Asia-Pacific Phenylketonuria Epidemiology (2016-2031)
5.5 Latin America Phenylketonuria Epidemiology (2016-2031)
5.6 Middle East & Africa Phenylketonuria Epidemiology (2016-2031)
6 Phenylketonuria Treatment Market Overview
6.1 Phenylketonuria Treatment Market Historical Value (2016-2022)
6.2 Phenylketonuria Treatment Market Forecast Value (2023-2031)
7 Phenylketonuria Treatment Market Landscape
7.1 Phenylketonuria Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Phenylketonuria Treatment: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Technology
8 Phenylketonuria Treatment Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Phenylketonuria Treatment Market Segmentation
9.1 Phenylketonuria Treatment Market by Disease Type
9.1.1 Market Overview
9.1.2 Hyperphenylalaninemia
9.1.3 Mild PKU
9.1.4 Moderate or Variant
9.1.5 Classic PKU
9.2 Phenylketonuria Treatment Market by Product Type
9.2.1 Market Overview
9.2.2 Dietary Supplements
9.2.3 Drugs
9.2.3.1 Kuvan
9.2.3.2 Playnziq
9.2.3.3 Others
9.3 Phenylketonuria Treatment Market by Route of Administration
9.3.1 Market Overview
9.3.2 Oral
9.3.3 Parenteral
9.3.4 Others
9.4 Phenylketonuria Treatment Market by Distribution Channel
9.4.1 Market Overview
9.4.2 Hospital Pharmacies
9.4.3 Retail Pharmacies
9.4.4 Online Pharmacies
9.4.5 Others
9.5 Phenylketonuria Treatment Market by Region
9.5.1 Market Overview
9.5.2 North America
9.5.3 Europe
9.5.4 Asia Pacific
9.5.5 Latin America
9.5.6 Middle East and Africa
10 North America Phenylketonuria Treatment Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Phenylketonuria Treatment Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Phenylketonuria Treatment Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Phenylketonuria Treatment Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Phenylketonuria Treatment Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Boehringer Ingelheim International GmbH
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Eisai Co., Ltd.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Pfizer, Inc
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Sanofi SA
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Teva Pharmaceutical Industries Ltd.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Aspen Holdings
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Mitsubishi Tanabe Pharma Corporation.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Abbott Laboratories
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 GlaxoSmithKline plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Bristol-Myers Squibb Company
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
22 Phenylketonuria Treatment - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global phenylketonuria treatment market reached a value of USD 0.88 billion in 2022.
The market is anticipated to grow at a CAGR of 9.3% during the forecast period of 2023-2031 to reach a value of USD 1.96 billion by 2031.
The major drivers of the market include the increase in the production and commercialisation of new drugs, increased research and development activities, rising health concerns, enhanced diagnostics facilities, improved health care infrastructure, increased population, and the growing investment in the development of drugs.
Growing prevalence of phenylketonuria and the rising awareness regarding its treatment are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, Middle East and Africa, Europe, and Asia Pacific with North America accounting for the largest share in the market.
Dietary supplement and drugs are the product types in the market. Drugs are further bifurcated into kuvan, palynziq, CNSA-001, and SYNB1618.
Based on route of administration, the market is divided into oral and parenteral.
The distribution channels are hospital pharmacies, online pharmacies, paediatric clinics, and drug stores.
The major players in the industry are BioMarin Pharmaceutical Inc., Synlogic, Inc., Retrophin, Inc., Codexis, Inc., SOM Innovation Biotech, S.A., and Homology Medicines, Inc., among others.
Analyst Review
The global phenylketonuria treatment market attained a value of nearly USD 446.7 million in 2020, driven by the growing prevalence of phenylketonuria. Aided increase in the production and commercialisation of new drugs and rising awareness regarding its treatment, the market is expected to witness further growth in the forecast period of 2023-2031, growing at a CAGR of 10%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Dietary supplement and drugs are the product types in the market. Drugs are further bifurcated into kuvan, palynziq, CNSA-001, and SYNB1618. Based on route of administration, the market is divided into oral and parenteral. The distribution channels are hospital pharmacies, online pharmacies, paediatric clinics, and drug stores. The major regional markets for phenylketonuria treatment market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa with North America accounting for the largest share in the market. The major players in the industry are BioMarin Pharmaceutical Inc., Synlogic, Inc., Retrophin, Inc., Codexis, Inc., SOM Innovation Biotech, S.A., and Homology Medicines, Inc., among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER